A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
A legfontosabb adatok
- Ki végzi
- Hoffmann-La Roche
- Hol
- Bardstown, Beaumont, Birmingham, Chamblee, Charleston, Dallas, Dayton, Grand Island, Harrisburg, Houston, Idaho Falls, Kingwood, Lafayette, Las Vegas, Lawrenceville, Macon, Miami, Middleburg Heights, Mishawaka, Pensacola, Richardson, San Antonio, Slidell, Smithfield, Sugar Land és West Jordan (Egyesült Államok)Mind a 28 helyszín megnézéseMég 3 másik országban, 23 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 1100 fő, tervezett
- Kezdés
- 2023. nov. 22.
- Várható befejezés
- 2027. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Baloxavir Marboxil
- A regiszteradat frissítve
- 2026. október 23.
Ki vehet részt
- Életkor
- 3 hét – 11 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Participants with symptoms suggestive of influenza based on investigator's judgement with diagnosis confirmed by a positive local influenza test within 24 hours before full study screening
- Participants with a negative severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 48 hours before full study screening
- Time interval between onset of influenza symptoms and the start of pre-dose examinations at screening is 48 hours or less
- [A] IP:
- Eligible to take part in Part A
- Lives in a household with a HHC willing to be recruited as full HHC; [B] HHCs:
- Each HHC living in the home of an IP at the time of IP treatment must be screened for partial or full-study HHC eligibility; [C] Partial HHC:
- Starts screening within 1 calendar day after IP treatment
- Negative influenza and SARS-CoV-2 test at screening after IP's treatment with baloxavir marboxil
- HHC lives in a household where 1 or more HHCs meet the full-study HHC requirements AND at least 1 full-study HHC has not received the influenza vaccine within 6 months prior to screening
- HHC lives in a household where 1 or more HHCs meet the full-study HHC requirements, and at least 1 full-study HHC has not received the influenza vaccine within 6 months prior to screening
- HHC lives with other HHCs (if applicable) who fulfill all the "partial HHC" criteria; [D] Full-study HHC:
- Fulfills the "partial HHC" criteria
- Agrees to participate in the full study
- Will reside in the IP's house for at least 12 of the next 15 days and will be present for scheduled study visits
- No influenza symptoms within 7 days prior to screening
- Does not have a moderate or worse active infections or infections requiring systemic or otherwise internally administered or otherwise internally administered antibiotic/antiviral/antifungal therapy
Ki nem vehet részt
- Severely immunocompromised participants (including participants receiving immunosuppressant therapy, or those with cancer or human immunodeficiency virus [HIV] infection) as defined by the investigator
- Participants with concurrent (non-influenza) infections requiring systemic anti-microbial and/or anti-viral therapy at the pre-dose examinations
- Treatment with baloxavir marboxil, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to screening
- Treatment with an investigational influenza-specific monoclonal antibody within 6 months or 5 half-lives, whichever is longer, prior to screening
- Treatment with an investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to screening
- Participants with severe influenza virus infection requiring inpatient treatment
- Known hypersensitivity to baloxavir marboxil or the drug product excipients
- Females who have commenced menarche (i.e., child-bearing potential)
- IPs who fulfil an exclusion criterion for Part A
- HHCs deemed to require influenza post-exposure prophylaxis with influenza antiviral treatment due to their risk of developing influenza-related complications in accordance with local guidelines or clinical practice
- HHCs diagnosed with influenza by health care professional in the past 4 weeks
Helyszínek itt: Egyesült Államok
Még 3 másik országban, 23 helyszínen
- Kentucky Pediatric Research CenterBardstown, Egyesült ÁllamokRésztvevőt keres
- Tekton Research - BeaumontBeaumont, Egyesült ÁllamokNo longer taking part
- Central Alabama ResearchBirmingham, Egyesült ÁllamokRésztvevőt keres
- Tekton Research - Chamblee GeorgiaChamblee, Egyesült ÁllamokNo longer taking part
- Coastal Pediatric ResearchCharleston, Egyesült ÁllamokNo longer taking part
- Oak Cliff Research Company, LLCDallas, Egyesült ÁllamokNo longer taking part
- Ohio Pediatric Research AssociationDayton, Egyesült ÁllamokNo longer taking part
- Velocity Clinical Research - Grand IslandGrand Island, Egyesült ÁllamokNo longer taking part
- Harrisburg Family Medical CenterHarrisburg, Egyesült ÁllamokRésztvevőt keres
- Pioneer Research SolutionsHouston, Egyesült ÁllamokRésztvevőt keres
- Mercury Clinical ResearchHouston, Egyesült ÁllamokNo longer taking part
- Clinical Research PrimeIdaho Falls, Egyesült ÁllamokRésztvevőt keres
- Frontier Clinical Research, LLCKingwood, Egyesült ÁllamokNo longer taking part
- Velocity Clinical Research, LafayetteLafayette, Egyesült ÁllamokRésztvevőt keres
- Machuca Family MedicineLas Vegas, Egyesült ÁllamokNo longer taking part
- Tekton Research LawrencevilleLawrenceville, Egyesült ÁllamokNo longer taking part
- Velocity Clinical Research at Primary Pediatrics MaconMacon, Egyesült ÁllamokNo longer taking part
- Kendall South Medical Center, IncMiami, Egyesült ÁllamokRésztvevőt keres
- Helios Clinical Research, Inc (former Ventavia Research Group)Middleburg Heights, Egyesült ÁllamokRésztvevőt keres
- Mishawaka Osteopathic ClinicMishawaka, Egyesült ÁllamokRésztvevőt keres
- Avanza Medical Research CenterPensacola, Egyesült ÁllamokNo longer taking part
- Oak Cliff Research Company, LLCRichardson, Egyesült ÁllamokNo longer taking part
- Sun Research InstituteSan Antonio, Egyesült ÁllamokNo longer taking part
- Tekton ResearchSan Antonio, Egyesült ÁllamokNo longer taking part
- Velocity Clinical Research, SlidellSlidell, Egyesült ÁllamokNo longer taking part
- Frontier Clinical ResearchSmithfield, Egyesült ÁllamokRésztvevőt keres
- Siena Research NetworkSugar Land, Egyesült ÁllamokRésztvevőt keres
- Velocity Clinical Research, Salt Lake CityWest Jordan, Egyesült ÁllamokNo longer taking part
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study consists of two parts: Part A Surveillance and Part B Transmission.
A teljes eredeti leírásKevesebb
The main purpose of Part A is to evaluate the prevalence of pre-dose and treatment-emergent amino acid substitutions in pediatric participants' <12 years with influenza treated with baloxavir marboxil.
Part B will include a subset of Part A participants who have household contacts (HHCs) recruited to the study. Part B will evaluate the incidence of onward influenza transmission from pediatric index participants (IPs) under 5 years of age and those aged 5 to under 12 years, treated with baloxavir marboxil, to their HHCs. Participants will no longer be enrolled to Part B Transmission as per protocol version 3.
A vizsgálat csoportja
- Baloxavir MarboxilA vizsgált kezelés
Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight and age). HHCs related to IPs will be enrolled but will not receive treatment.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase IIIb Multicenter, Single-arm, Open-label Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Patients With Influenza and Transmission of Influenza to Household Contacts
- A regiszteradat frissítve
- 2026. október 23.